VEGFD and lymphangioleiomyomatosis: ATS/JRS guidelines regarded serum VEGF-D as a diagnostic biomarker for LAM patients with HRCT showing typical thin-walled cystic change in the lung, with a diagnostic threshold of 800 pg/ml [10].